GlassScriptPhysician profile
Hector A Fabregas
NPI 1194933556
$6,943.29
in general payments reported to CMS, 2019-2025
51 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $442 · 2021: $906 · 2022: $889 · 2023: $1,253 · 2024: $1,660 · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,263.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $946.47 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $770.60 | 2019-2025 | |
| Novo Nordisk INC | $618.33 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $603.81 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $450.45 | 2021-2025 | |
| Amgen INC. | $359.82 | 2019-2025 | Repatha, Otezla, Repatha |
| Medtronic, INC. | $280.82 | 2023-2024 | Micra |
| Lilly USA, LLC | $265.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $259.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.02 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $192.58 | 2020-2025 | Rexulti, Jynarque |
| Boston Scientific Corporation | $160.85 | 2021-2023 | Wavewriter Alpha Prime 16 |
| Amarin Pharma, INC. | $135.14 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.18 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $125.14 | 2024 | Voquezna |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Fabregas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.